While there is no experience in the treatment of overdose with rifabutin capsules, clinical experience with rifamycins suggests that gastric lavage to evacuate gastric contents (within a few hours of overdose), followed by instillation of an activated charcoal slurry into the stomach, may help absorb any remaining drug from the gastrointestinal tract.
Rifabutin is 85% protein bound and distributed extensively into tissues (Vss:8 to 9 L/kg). It is not primarily excreted via the urinary route (less than 10% as unchanged drug); therefore, neither hemodialysis nor forced diuresis is expected to enhance the systemic elimination of unchanged rifabutin from the body in a patient with an overdose of rifabutin.
It is recommended that rifabutin capsules USP be administered at a dose of 300 mg once daily. For those patients with propensity to nausea, vomiting, or other gastrointestinal upset, administration of rifabutin at doses of 150 mg twice daily taken with food may be useful.
For patients with severe renal impairment (creatinine clearance less than 30 mL/min), consider reducing the dose of rifabutin by 50%, if toxicity is suspected. No dosage adjustment is required for patients with mild to moderate renal impairment. Reduction of the dose of rifabutin may also be needed for patients receiving concomitant treatment with certain other drugs (see PRECAUTIONS-Drug Interactions).
Mild hepatic impairment does not require a dose modification. The pharmacokinetics of rifabutin in patients with moderate and severe hepatic impairment is not known.
Rifabutin Capsules USP are supplied as size ’0′ capsules having opaque red-brown cap imprinted with ‘LU’ in white ink and opaque red-brown body imprinted with ‘R01′ in white ink, containing red-violet granular powder equivalent to 150 mg of rifabutin USP.
Rifabutin Capsules USP are available as follows:
Bottles of 60 capsules — NDC 68180-285-07
Bottles of 100 capsules — NDC 68180-285-01
Store at 25°C (77°F); excursions permitted to 15 to 30°C (59 to 86°F) [see USP Controlled Room Temperature].
Keep tightly closed and dispense in a tight container as defined in the USP. Protect from light and from excessive heat.
Lupin Pharmaceuticals, Inc.
Baltimore, Maryland 21202
Aurangabad 431 210
Revised: December 2018 ID#: 257561
A Bottle Label containing 100 capsules
|RIFABUTIN rifabutin capsule|
|Labeler — Lupin Pharmaceuticals, Inc. (089153071)|
|Registrant — LUPIN LIMITED (675923163)|
|LUPIN LIMITED||862272739||MANUFACTURE (68180-285)|
Revised: 11/2019 Lupin Pharmaceuticals, Inc.
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.